Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics business, presented new pre-scientific data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010 http://www.metronidazole500mg.com/category/drugs-addiction . ALN-TTR01 is a systemically shipped RNAi therapeutic being developed for the treatment of transthyretin -mediated amyloidosis , including familial amyloidotic polyneuropathy and familial amyloidotic cardiomyopathy . These new pre-medical data demonstrate - for the very first time - that treatment with an RNAi therapeutic can result in regression of pre-existing pathogenic TTR deposits in peripheral tissues.
She added, The pre-clinical data with ALN-TTR01 obtained to time are promising, especially recent results showing regression of pathogenic TTR tissue deposition in the mouse transgenic model. By all accounts, I am excited about the translation of the new agent into clinical trials as there are few options for individuals suffering from this disease. ALN-TTR01 is in clinical development using steady nucleic acid-lipid particles delivery technology created in collaboration with Tekmira Pharmaceuticals Corporation.. Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01 Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today it has initiated dosing in a Phase I human clinical research with ALN-TTR01 announced. The study is aimed at evaluating the security and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis , and is also designed to provide preliminary data on human proof concept predicated on measurements of TTR serum levels.